BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 16542198)

  • 1. Lack of sex-related differences in saquinavir pharmacokinetics in an HIV-seronegative cohort.
    Robertson SM; Formentini E; Alfaro RM; Natarajan V; Falloon J; Penzak SR
    Br J Clin Pharmacol; 2006 Apr; 61(4):379-88. PubMed ID: 16542198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of in vivo correlation between indinavir and saquinavir exposure and cytochrome P450 3A phenotype as assessed with oral midazolam as a phenotype probe.
    Robertson SM; Formentini E; Alfaro RM; Falloon J; Penzak SR
    Pharmacotherapy; 2006 Aug; 26(8):1051-9. PubMed ID: 16863481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of saquinavir/ritonavir (1000/100 mg bid) on the pharmacokinetics of methadone in opiate-dependent HIV-negative patients on stable methadone maintenance therapy.
    Jamois C; Smith P; Morrison R; Riek M; Patel A; Schmitt C; Morcos PN; Zhang X
    Addict Biol; 2009 Jul; 14(3):321-7. PubMed ID: 19523046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex-related differences in the pharmacokinetics of once-daily saquinavir soft-gelatin capsules boosted with low-dose ritonavir in patients infected with human immunodeficiency virus type 1.
    Pai MP; Schriever CA; Diaz-Linares M; Novak RM; Rodvold KA
    Pharmacotherapy; 2004 May; 24(5):592-9. PubMed ID: 15162893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
    Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
    J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults.
    Ribera E; Lopez RM; Diaz M; Pou L; Ruiz L; Falcó V; Crespo M; Azuaje C; Ruiz I; Ocaña I; Clotet B; Pahissa A
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4256-62. PubMed ID: 15504850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir.
    Hsu A; Granneman GR; Cao G; Carothers L; el-Shourbagy T; Baroldi P; Erdman K; Brown F; Sun E; Leonard JM
    Clin Pharmacol Ther; 1998 Apr; 63(4):453-64. PubMed ID: 9585800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patients infected with human immunodeficiency virus.
    Khaliq Y; Gallicano K; Venance S; Kravcik S; Cameron DW
    Clin Pharmacol Ther; 2000 Dec; 68(6):637-46. PubMed ID: 11180024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers.
    Winston A; Back D; Fletcher C; Robinson L; Unsworth J; Tolowinska I; Schutz M; Pozniak AL; Gazzard B; Boffito M
    AIDS; 2006 Jun; 20(10):1401-6. PubMed ID: 16791014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of saquinavir/ritonavir on P-glycoprotein activity in healthy volunteers using digoxin as a probe.
    Schmitt C; Kaeser B; Riek M; Bech N; Kreuzer C
    Int J Clin Pharmacol Ther; 2010 Mar; 48(3):192-9. PubMed ID: 20197013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of food and ranitidine on saquinavir pharmacokinetics and gastric pH in healthy volunteers.
    Kakuda TN; Falcon RW
    Pharmacotherapy; 2006 Aug; 26(8):1060-8. PubMed ID: 16863482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects.
    Boffito M; Back D; Stainsby-Tron M; Hill A; Di Perri G; Moyle G; Nelson M; Tomkins J; Gazzard B; Pozniak A
    Br J Clin Pharmacol; 2005 Jan; 59(1):38-42. PubMed ID: 15606438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic characterization of a human immunodeficiency virus protease inhibitor, saquinavir, during ethanol intake in rats.
    Shibata N; Kageyama M; Kishida T; Kimura K; Yoshikawa Y; Kuwahara T; Toh J; Shirasaka T; Takada K
    Biopharm Drug Dispos; 2003 Nov; 24(8):335-44. PubMed ID: 14595702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Saquinavir 500 mg film-coated tablets demonstrate bioequivalence to saquinavir 200 mg hard capsules when boosted with twice-daily ritonavir in healthy volunteers.
    Bittner B; Riek M; Holmes B; Grange S
    Antivir Ther; 2005; 10(7):803-10. PubMed ID: 16312177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic study of saquinavir 500 mg plus ritonavir (1000/100 mg twice a day) in HIV-positive pregnant women.
    Martinez-Rebollar M; Lonca M; Perez I; Soy D; Brunet M; Martin R; Coll O; Hernandez S; Laguno M; Milinkovic A; Larrousse M; Calvo M; Blanco JL; Martínez E; Gatell JM; Mallolas J
    Ther Drug Monit; 2011 Dec; 33(6):772-7. PubMed ID: 22105596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacokinetics, safety and efficacy of boosted saquinavir tablets in HIV type-1-infected pregnant women.
    van der Lugt J; Colbers A; Molto J; Hawkins D; van der Ende M; Vogel M; Wyen C; Schutz M; Koopmans P; Ruxrungtham K; Richter C; Burger D;
    Antivir Ther; 2009; 14(3):443-50. PubMed ID: 19474478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe.
    Schmitt C; Hofmann C; Riek M; Patel A; Zwanziger E
    Pharmacotherapy; 2009 Oct; 29(10):1175-81. PubMed ID: 19792991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors.
    von Hentig N; Babacan E; Lennemann T; Knecht G; Carlebach A; Harder S; Staszewski S; Haberl A
    J Antimicrob Chemother; 2008 Sep; 62(3):579-82. PubMed ID: 18477709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of garlic supplements on the pharmacokinetics of saquinavir.
    Piscitelli SC; Burstein AH; Welden N; Gallicano KD; Falloon J
    Clin Infect Dis; 2002 Jan; 34(2):234-8. PubMed ID: 11740713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of ABCB1 polymorphism on the pharmacokinetics of saquinavir alone and in combination with ritonavir.
    la Porte CJ; Li Y; Béïque L; Foster BC; Chauhan B; Garber GE; Cameron DW; van Heeswijk RP
    Clin Pharmacol Ther; 2007 Oct; 82(4):389-95. PubMed ID: 17361121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.